Why the study?
Does recombinant nematode anticoagulant protein c2 (rNAPc2) prevent venous thromboembolism in patients undergoing total knee replacement?
Population
293 patients undergoing elective, unilateral total knee replacement
Design
Cohort, open-label (with independent, blinded Central Adjudication Committee)
Follow-up
day 7+/-2
Authors
Loading...
rNAPc2 3.0 μg/kg was associated with low post-TKR VTE and bleeding rates; hypothesis-generating and requires RCTs before practice change.
Does recombinant nematode anticoagulant protein c2 (rNAPc2) prevent venous thromboembolism in patients undergoing total knee replacement?
Recombinant nematode anticoagulant protein c2 (rNAPc2) at a dose of 3.0 microgram/kg shows promising efficacy and safety for the prevention of venous thromboembolism following total knee replacement.
Lee et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: